These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
368 related items for PubMed ID: 1668114
1. Pharmacological properties of YM461, a new orally active platelet-activating factor antagonist. Yamada T, Saito M, Mase T, Hara H, Nagaoka H, Murase K, Tomioka K. Lipids; 1991 Dec; 26(12):1179-83. PubMed ID: 1668114 [Abstract] [Full Text] [Related]
2. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist. Herbert JM, Bernat A, Valette G, Gigo V, Lale A, LaPlace MC, Lespy L, Savi P, Maffrand JP, Le Fur G. J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029 [Abstract] [Full Text] [Related]
3. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride. Imanishi N, Murakami-Uchida M, Koike H, Natsume Y, Morooka S. Arzneimittelforschung; 1994 Mar; 44(3):317-22. PubMed ID: 8192697 [Abstract] [Full Text] [Related]
4. Pharmacological properties of YM264, a potent and orally active antagonist of platelet-activating factor. Yamada T, Tomioka K, Saito M, Horie M, Mase T, Hara H, Nagaoka H. Arch Int Pharmacodyn Ther; 1990 Mar; 308():123-36. PubMed ID: 2099131 [Abstract] [Full Text] [Related]
5. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist. Herbert JM, Fraisse L, Bachy A, Valette G, Savi P, Laplace MC, Lassalle J, Roche B, Lale A, Keane PE. J Lipid Mediat; 1993 Aug; 8(1):31-51. PubMed ID: 8257776 [Abstract] [Full Text] [Related]
6. Effect of Y-24180, a long-acting antagonist to platelet-activating factor (PAF), on PAF-induced reactions: a relationship between the partial structure of the compound and its duration of the action. Kagoshima M, Tomomatsu N, Iwahisa Y, Yamaguchi S, Kawakami Y, Terasawa M. Pharmacology; 1997 May; 54(5):261-70. PubMed ID: 9380772 [Abstract] [Full Text] [Related]
7. Biological effect of orally active platelet-activating factor receptor antagonist SM-10661. Komuro Y, Imanishi N, Uchida M, Morooka S. Mol Pharmacol; 1990 Sep; 38(3):378-84. PubMed ID: 2402227 [Abstract] [Full Text] [Related]
8. Pharmacological actions of Y-24180, a new specific antagonist of platelet activating factor (PAF): II. Interactions with PAF and benzodiazepine receptors. Takehara S, Mikashima H, Muramoto Y, Terasawa M, Setoguchi M, Tahara T. Prostaglandins; 1990 Dec; 40(6):571-83. PubMed ID: 1965554 [Abstract] [Full Text] [Related]
9. Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist. Tsunoda H, Sakuma Y, Harada K, Muramoto K, Katayama S, Horie T, Shimomura N, Clark R, Miyazawa S, Okano K. Arzneimittelforschung; 1990 Nov; 40(11):1201-5. PubMed ID: 2085331 [Abstract] [Full Text] [Related]
10. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents. Terashita Z, Kawamura M, Takatani M, Tsushima S, Imura Y, Nishikawa K. J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121 [Abstract] [Full Text] [Related]
11. Pharmacology of a potent platelet-activating factor antagonist: Ro 24-4736. Crowley HJ, Yaremko B, Selig WM, Janero DR, Burghardt C, Welton AF, O'Donnell M. J Pharmacol Exp Ther; 1991 Oct; 259(1):78-85. PubMed ID: 1656030 [Abstract] [Full Text] [Related]
12. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). Merlos M, Giral M, Balsa D, Ferrando R, Queralt M, Puigdemont A, García-Rafanell J, Forn J. J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188 [Abstract] [Full Text] [Related]
13. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor. Heuer HO, Casals-Stenzel J, Muacevic G, Weber KH. J Pharmacol Exp Ther; 1990 Dec; 255(3):962-8. PubMed ID: 2262914 [Abstract] [Full Text] [Related]
15. 2-(3-Pyridyl)thiazolidine-4-carboxamide derivatives. III.) Synthesis of metabolites and metabolism of 2-(3-pyridyl)thiazolidine-4-carboxamides YM461 and YM264 as platelet-activating factor (PAF) receptor antagonists. Suzuki T, Nagaoka H, Hara H, Takeuchi M, Saito M, Yamada T, Tomioka K, Matsumoto H, Takanuki K, Mase T. Chem Pharm Bull (Tokyo); 1999 Feb; 47(2):165-70. PubMed ID: 10071851 [Abstract] [Full Text] [Related]
16. Effects of platelet activating factor receptor antagonists on intracellular platelet activating factor function in neutrophils. Koike H, Imanishi N, Natsume Y, Morooka S. Eur J Pharmacol; 1994 Nov 15; 269(3):299-309. PubMed ID: 7895770 [Abstract] [Full Text] [Related]
17. Ex vivo effects of SR 27417, a novel PAF antagonist, on rabbit platelet aggregation and [3H]-PAF binding. Herbert JM, Laplace MC, Maffrand JP. J Lipid Mediat; 1992 Feb 15; 5(1):1-12. PubMed ID: 1327264 [Abstract] [Full Text] [Related]
18. MK 287: a potent, specific, and orally active receptor antagonist of platelet-activating factor. Hwang SB, Lam MH, Szalkowski DM, MacIntyre DE, Bach TJ, Luell S, Meuer R, Sahoo SP, Alberts AW, Chabala JC. J Lipid Mediat; 1993 Jun 15; 7(2):115-34. PubMed ID: 8400114 [Abstract] [Full Text] [Related]
19. Pharmacological profile of UK-74,505, a novel and selective PAF antagonist with potent and prolonged oral activity. Parry MJ, Alabaster VA, Cheeseman HE, Cooper K, deSouza RN, Keir RF. J Lipid Mediat Cell Signal; 1994 Sep 15; 10(3):251-68. PubMed ID: 7812676 [Abstract] [Full Text] [Related]
20. 2-(3-Pyridyl)thiazolidine-4-carboxamides. 1. Novel orally active antagonists of platelet-activating factor (PAF). Nagaoka H, Hara H, Suzuki T, Takahashi T, Takeuchi M, Matsuhisa A, Saito M, Yamada T, Tomioka K, Mase T. Chem Pharm Bull (Tokyo); 1997 Oct 15; 45(10):1659-64. PubMed ID: 9353894 [Abstract] [Full Text] [Related] Page: [Next] [New Search]